Welcome to our dedicated page for ORGANON & CO SEC filings (Ticker: OGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organon & Co. filings document the regulatory record for a NYSE-listed global healthcare company with Women's Health and General Medicines portfolios, including biosimilars. Form 8-K reports cover operating and financial results, company presentations, clinical or regulatory disclosures, material agreements, and other material events tied to the healthcare portfolio.
Proxy and governance filings describe board composition, executive compensation, shareholder voting matters, equity-award disclosures, and common stock registered under the Exchange Act. The filing record also includes disclosures on board and committee changes, audit committee review matters, capital structure, and exhibits filed in Inline XBRL.
Organon & Co. interim CEO Joseph T. Morrissey Jr. exercised 9,752 Restricted Stock Units (RSUs) into common stock on March 29, 2026. Each RSU converts into one share of Organon common stock, and the award vests in three equal installments on March 29, 2025, 2026, and 2027. To satisfy tax obligations related to this vesting, 2,779 common shares were withheld at a reference price of $5.84 per share. After these compensation-related transactions, Morrissey holds 105,543.923 common shares directly, indicating this filing reflects routine equity award vesting and associated tax withholding rather than an open-market stock sale.
Organon & Co ownership update: The Vanguard Group filed an amendment noting an internal realignment on January 12, 2026 that led certain subsidiaries and business divisions to report beneficial ownership separately under SEC Release No. 34-39538. The filing states The Vanguard Group beneficially owns 0 shares of Organon common stock, representing 0% of the class. The statement explains the subsidiaries pursue the same investment strategies previously used and that Vanguard Inc. no longer is deemed to beneficially own those securities. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Organon & Co. Chief Human Resources Officer Aaron Falcione reported equity compensation activity in company common stock. On February 27, 2026, he acquired 23,805 shares and 6,717 shares at no cost as stock awards tied to performance share units granted in August 2023, following certification of performance goals and related dividend equivalents. To cover tax obligations, he disposed of 8,705 shares at $7.17 and 2,301 shares at $7.23 through tax-withholding dispositions rather than open-market sales. After these transactions, he directly owned 84,109.071 shares of Organon common stock.
Organon & Co. Chief Financial Officer Matthew M. Walsh reported equity compensation activity in common stock. He acquired 42,599 shares and 12,020 shares at no cost upon performance share units and related dividend equivalents vesting. To satisfy tax obligations, he disposed of 14,887 shares at $7.17 and 4,117 shares at $7.23 through tax-withholding transactions, leaving a six-figure direct holding in Organon stock.
Organon & Co. executive Nisita Vittorio reported equity compensation activity involving common stock on February 27, 2026. She received 16,287 shares tied to performance share units granted on August 11, 2023, after performance goals were certified, plus 4,596 additional shares related to dividend equivalents.
To satisfy tax obligations, 6,210 shares at $7.17 and 1,575 shares at $7.23 were disposed of through tax-withholding transactions rather than open-market sales. After these awards and withholdings, she directly held 58,284.158 shares of Organon common stock.
Organon & Co.'s Chief Information Officer Rachel A. Stahler reported equity award activity in the company's common stock. She acquired 23,178 shares and 6,540 shares at no cost, reflecting performance share units granted on August 11, 2023 whose performance-vesting conditions were certified by a board committee, plus related dividend equivalents. To cover tax withholding on these releases, 8,475 shares at $7.17 and 2,240 shares at $7.23 were disposed of through share withholding rather than open-market sales. Following these transactions, she directly owns 98,310.292 shares, including 2,076.678 shares from prior dividend equivalents net of withholding tax.
Organon & Co. general counsel Kirke Weaver reported stock-based compensation and related tax-withholding transactions in company common stock. On February 27, 2026, Weaver acquired 21,925 shares tied to performance share units granted on August 11, 2023, after Organon’s Talent Committee certified that performance goals were met.
Weaver also acquired 6,186 shares representing dividend equivalents on those performance units, and 1,832.163 additional shares from prior dividend equivalents were added to holdings. To cover tax liabilities, 6,815 shares at $7.17 and 1,763 shares at $7.23 were disposed through tax-withholding transactions. Following these movements, Weaver directly owned 73,854.163 common shares.
Organon & Co. interim CEO Joseph T. Morrissey Jr. reported equity compensation-related share movements in Organon common stock. On February 27, 2026, he acquired 27,564 shares tied to performance share units granted on August 11, 2023, after performance goals were certified, and an additional 7,777 shares were granted as related awards and dividend equivalents at no cost.
On the same date, 8,054 shares at $7.17 per share and 2,216 shares at $7.23 per share were surrendered in tax-withholding dispositions to cover exercise price or tax obligations. After these transactions and the inclusion of 1,938.068 dividend-equivalent shares that were not previously reportable, he directly held about 98,571 shares of Organon common stock.
Organon & Co. is a global healthcare company focused on women’s health and general medicines, generating $6.2 billion of revenue in 2025, with about 74% from outside the United States. Women’s health contributed $1.8 billion, biosimilars $691 million, and established brands $3.7 billion.
The company is prioritizing debt reduction by cutting its dividend payout, divesting non-core assets, restructuring to lower costs, and paying down long‑term debt. In January 2026 it sold the Jada postpartum hemorrhage system to Laborie for up to $465 million, including potential earn‑outs.
Organon operates six manufacturing sites across Europe, Latin America and Asia and employs over 10,000 people. It faces material weaknesses in internal control over financial reporting tied to Nexplanon wholesaler sales practices and is implementing a remediation plan under interim leadership, including an Interim CEO and Executive Chair, while a search for a permanent CEO is underway.
Organon & Co. reported that its Audit Committee has completed an independent review into the timing of the company’s past biosimilar purchases from a supplier. With assistance from outside counsel, the review concluded that no action is required, found no evidence of improper conduct, and identified no matters requiring adjustments to previously issued financial statements or SEC disclosures. The company also stated that it intends to timely file its Form 10-K for the year ended December 31, 2025, while noting that these plans involve forward-looking statements subject to risks and uncertainties.